Suppr超能文献

从成功的人类疫苗中汲取的经验教训:通过剖析衣壳蛋白来确定关键表位。

Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

作者信息

Zhang Xiao, Xin Lu, Li Shaowei, Fang Mujin, Zhang Jun, Xia Ningshao, Zhao Qinjian

机构信息

a State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Institute of Diagnostics and Vaccine Development in Infectious Diseases; Xiamen University ; Xiamen , Fujian , PR China.

出版信息

Hum Vaccin Immunother. 2015;11(5):1277-92. doi: 10.1080/21645515.2015.1016675.

Abstract

Recombinant VLP-based vaccines have been successfully used against 3 diseases caused by viral infections: Hepatitis B, cervical cancer and hepatitis E. The VLP approach is attracting increasing attention in vaccine design and development for human and veterinary use. This review summarizes the clinically relevant epitopes on the VLP antigens in successful human vaccines. These virion-like epitopes, which can be delineated with molecular biology, cryo-electron microscopy and x-ray crystallographic methods, are the prerequisites for these efficacious vaccines to elicit functional antibodies. The critical epitopes and key factors influencing these epitopes are discussed for the HEV, HPV and HBV vaccines. A pentamer (for HPV) or a dimer (for HEV and HBV), rather than a monomer, is the basic building block harboring critical epitopes for the assembly of VLP antigen. The processing and formulation of VLP-based vaccines need to be developed to promote the formation and stabilization of these epitopes in the recombinant antigens. Delineating the critical epitopes is essential for antigen design in the early phase of vaccine development and for critical quality attribute analysis in the commercial phase of vaccine manufacturing.

摘要

基于重组病毒样颗粒(VLP)的疫苗已成功用于预防由病毒感染引起的三种疾病:乙型肝炎、宫颈癌和戊型肝炎。VLP方法在人用和兽用疫苗设计与开发中受到越来越多的关注。本综述总结了成功的人用疫苗中VLP抗原上与临床相关的表位。这些病毒样表位可用分子生物学、冷冻电子显微镜和X射线晶体学方法进行描绘,是这些有效疫苗引发功能性抗体的先决条件。本文讨论了戊型肝炎病毒(HEV)、人乳头瘤病毒(HPV)和乙型肝炎病毒(HBV)疫苗的关键表位以及影响这些表位的关键因素。五聚体(针对HPV)或二聚体(针对HEV和HBV)而非单体,是承载VLP抗原组装关键表位的基本构建单元。需要开发基于VLP的疫苗的加工和配方,以促进这些表位在重组抗原中的形成和稳定。描绘关键表位对于疫苗开发早期阶段的抗原设计以及疫苗生产商业阶段的关键质量属性分析至关重要。

相似文献

1
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.
Hum Vaccin Immunother. 2015;11(5):1277-92. doi: 10.1080/21645515.2015.1016675.
2
Generation in yeast and antigenic characterization of hepatitis E virus capsid protein virus-like particles.
Appl Microbiol Biotechnol. 2018 Jan;102(1):185-198. doi: 10.1007/s00253-017-8622-9. Epub 2017 Nov 15.
3
Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
Vaccine. 2019 Jun 12;37(27):3529-3534. doi: 10.1016/j.vaccine.2019.05.011. Epub 2019 May 27.
4
Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
Vaccine. 2016 Nov 21;34(48):5871-5877. doi: 10.1016/j.vaccine.2016.10.045. Epub 2016 Oct 25.
5
Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®).
Vaccine. 2014 Jul 7;32(32):4039-50. doi: 10.1016/j.vaccine.2014.05.064. Epub 2014 Jun 2.
7
Epitope engineering and molecular metrics of immunogenicity: a computational approach to VLP-based vaccine design.
Vaccine. 2013 Oct 1;31(42):4841-7. doi: 10.1016/j.vaccine.2013.07.075. Epub 2013 Aug 9.
8
Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine.
Vaccine. 2017 Mar 14;35(12):1590-1593. doi: 10.1016/j.vaccine.2017.02.007. Epub 2017 Feb 17.

引用本文的文献

1
Discovery of novel HBV core protein inhibitors by high throughput virtual screening.
Sci Rep. 2025 Apr 16;15(1):13054. doi: 10.1038/s41598-025-97242-6.
2
Protein Expression Platforms and the Challenges of Viral Antigen Production.
Vaccines (Basel). 2024 Nov 28;12(12):1344. doi: 10.3390/vaccines12121344.
3
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.
Int J Mol Sci. 2023 Aug 19;24(16):12963. doi: 10.3390/ijms241612963.
4
Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus.
Front Immunol. 2023 Jun 27;14:1160260. doi: 10.3389/fimmu.2023.1160260. eCollection 2023.
5
Engineering a Virus-like Particle to Display Peptide Insertions Using an Apparent Fitness Landscape.
Biomacromolecules. 2020 Oct 12;21(10):4194-4204. doi: 10.1021/acs.biomac.0c00987. Epub 2020 Sep 3.
6
Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines.
Viruses. 2020 Apr 27;12(5):488. doi: 10.3390/v12050488.
8
Functional epitopes on hepatitis E virions and recombinant capsids are highly conformation-dependent.
Hum Vaccin Immunother. 2020 Jul 2;16(7):1554-1564. doi: 10.1080/21645515.2019.1703454. Epub 2020 Jan 29.
9
Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation.
Viruses. 2020 Jan 16;12(1):109. doi: 10.3390/v12010109.
10
Recent trends and advances in microbe-based drug delivery systems.
Daru. 2019 Dec;27(2):799-809. doi: 10.1007/s40199-019-00291-2. Epub 2019 Aug 2.

本文引用的文献

1
Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody.
Cell Res. 2015 May;25(5):604-20. doi: 10.1038/cr.2015.34. Epub 2015 Mar 20.
3
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.
Lancet. 2014 Dec 6;384(9959):2046-52. doi: 10.1016/S0140-6736(14)61185-5. Epub 2014 Aug 14.
4
Maturation of the human papillomavirus 16 capsid.
mBio. 2014 Aug 5;5(4):e01104-14. doi: 10.1128/mBio.01104-14.
5
Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®).
Vaccine. 2014 Jul 7;32(32):4039-50. doi: 10.1016/j.vaccine.2014.05.064. Epub 2014 Jun 2.
6
Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes.
Vaccine. 2014 May 19;32(24):2859-65. doi: 10.1016/j.vaccine.2014.02.025. Epub 2014 Mar 22.
7
Subviral particle as vaccine and vaccine platform.
Curr Opin Virol. 2014 Jun;6:24-33. doi: 10.1016/j.coviro.2014.02.009. Epub 2014 Mar 21.
8
Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58.
Clin Vaccine Immunol. 2014 Apr;21(4):587-93. doi: 10.1128/CVI.00773-13. Epub 2014 Feb 26.
9
Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen.
Hum Vaccin Immunother. 2014;10(4):1013-23. doi: 10.4161/hv.27753. Epub 2014 Feb 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验